An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies

Virology

Volumn 418, Issue 1, 2011, Pages 67-73

  Xu, Chungui ^a   Meng, Xiangzhi ^a   Yan, Bo ^a   Crotty, Shane ^b   Deng, Junpeng ^c   Xiang, Yan ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

A13; Antibody; Poxvirus; Smallpox; Vaccine; Vaccinia

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 11F7; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG TARGETING; EPITOPE MAPPING; FEMALE; GENETIC CONSERVATION; INFECTION PREVENTION; MONKEYPOX VIRUS; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN BINDING; SMALLPOX; SMALLPOX VIRUS; SURVIVAL RATE; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BODY WEIGHT; CONSERVED SEQUENCE; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MONKEYPOX VIRUS; NEUTRALIZATION TESTS; PLAQUE ASSAY; RODENT DISEASES; SURVIVAL ANALYSIS; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS; VIRAL ENVELOPE PROTEINS;

MONKEYPOX VIRUS; MURINAE; MUS; ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 80052033150     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.06.029     Document Type: Article

References (38)

1. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Pannell L.K., Lebowitz J., Fogg C., White C.L., Moss B., Cohen G.H., Eisenberg R.J. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 2005, 341(1):59-71.
2. Bell E., Shamim M., Whitbeck J.C., Sfyroera G., Lambris J.D., Isaacs S.N. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 2004, 325(2):425-431.
3. Benhnia M.R., Mccausland M.M., Su H.P., Singh K., Hoffmann J., Davies D.H., Felgner P.L., Head S., Sette A., Garboczi D.N., Crotty S. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J. Virol. 2008, 82(7):3751-3768.
4. Benhnia M.R., Mccausland M.M., Moyron J., Laudenslager J., Granger S., Rickert S., Koriazova L., Kubo R., Kato S., Crotty S. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 2009, 83(3):1201-1215.
5. Chung C.S., Chen C.H., Ho M.Y., Huang C.Y., Liao C.L., Chang W. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J. Virol. 2006, 80(5):2127-2140.
6. Condit R.C., Moussatche N., Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 2006, 66:31-124.
7. Davies D.H., Mccausland M.M., Valdez C., Huynh D., Hernandez J.E., Mu Y., Hirst S., Villarreal L., Felgner P.L., Crotty S. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 2005, 79(18):11724-11733.
8. Davies D.H., Molina D.M., Wrammert J., Miller J., Hirst S., Mu Y., Pablo J., Unal B., Nakajima-Sasaki R., Liang X., Crotty S., Karem K.L., Damon I.K., Ahmed R., Villarreal L., Felgner P.L. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 2007, 7(10):1678-1686.
9. Earl P.L., Moss B., Wyatt L.S., Carroll M.W. Generation of recombinant vaccinia viruses. Current Protocols in Molecular Biology 1998, 16.17.1-16.17.19. John Wiley & Sons, Inc. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (Eds.).
10. Fogg C.N., Americo J.L., Earl P.L., Resch W., Aldaz-Carroll L., Eisenberg R.J., Cohen G.H., Moss B. Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J. Virol. 2008, 82(16):8022-8029.
11. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 2003, 37(2):251-271.
12. Galmiche M.C., Goenaga J., Wittek R., Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 1999, 254(1):71-80.
13. He Y., Manischewitz J., Meseda C.A., Merchlinsky M., Vassell R.A., Sirota L., Berkower I., Golding H., Weiss C.D. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine-induced immunity. J. Infect. Dis. 2007, 196(7):1026-1032.
14. Hopkins R.J., Lane J.M. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin. Infect. Dis. 2004, 39(6):819-826.
15. Hsiao J.C., Chung C.S., Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J. Virol. 1999, 73(10):8750-8761.
16. Ichihashi Y., Oie M. Neutralizing epitope on penetration protein of vaccinia virus. Virology 1996, 220(2):491-494.
17. Isaacs S.N., Kotwal G.J., Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(2):628-632.
18. Kochan G., Escors D., Gonzalez J.M., Casasnovas J.M., Esteban M. Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell. Microbiol. 2008, 10(1):149-164.
19. Krumm B., Meng X., Li Y., Xiang Y., Deng J. Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(52):20711-20715.
20. Law M., Putz M.M., Smith G.L. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J. Gen. Virol. 2005, 86(4):991-1000. 10.1099/vir.0.80660-0.
21. Lustig S., Fogg C., Whitbeck J.C., Moss B. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 2004, 328(1):30-35.
22. Lustig S., Fogg C., Whitbeck J.C., Eisenberg R.J., Cohen G.H., Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 2005, 79(21):13454-13462.
23. Mccausland M.M., Benhnia M.R., Crickard L., Laudenslager J., Granger S.W., Tahara T., Kubo R., Koriazova L., Kato S., Crotty S. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir. Ther. 2010, 15(4):661-675.
24. Meng X., Chao J., Xiang Y. Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L. Virology 2008, 372(2):372-383.
25. Meng X., Zhong Y., Embry A., Yan B., Lu S., Zhong G., Xiang Y. Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus. Virology 2011, 409(2):271-279.
26. Moss B. Poxviridae: the viruses and their replication. Fields Virology 2007, 2905-2946. Lippincott Williams & Wilkins, Philadelphia, Vol. 2, 2 vols. D.M. Knipe, P.M. Howley (Eds.).
27. Nelson G.E., Sisler J.R., Chandran D., Moss B. Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 2008, 380(2):394-401.
28. Parker S., Nuara A., Buller R.M., Schultz D.A. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2007, 2(1):17-34.
29. Putz M.M., Midgley C.M., Law M., Smith G.L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med. 2006, 12(11):1310-1315.
30. Rodriguez J.F., Janeczko R., Esteban M. Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J. Virol. 1985, 56(2):482-488.
31. Rodriguez D., Esteban M., Rodriguez J.R. Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis. J. Virol. 1995, 69(8):4640-4648.
32. Sakhatskyy P., Wang S., Chou T.H., Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006, 355(2):164-174.
33. Salmons T., Kuhn A., Wylie F., Schleich S., Rodriguez J.R., Rodriguez D., Esteban M., Griffiths G., Locker J.K. Vaccinia virus membrane proteins p8 and p16 are cotranslationally inserted into the rough endoplasmic reticulum and retained in the intermediate compartment. J. Virol. 1997, 71(10):7404-7420.
34. Smith G.L., Vanderplasschen A., Law M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 2002, 83(12):2915-2931.
35. Unger B., Traktman P. Vaccinia virus morphogenesis: a13 phosphoprotein is required for assembly of mature virions. J. Virol. 2004, 78(16):8885-8901.
36. Wallengren K., Risco C., Krijnse-Locker J., Esteban M., Rodriguez D. The A17L gene product of vaccinia virus is exposed on the surface of IMV. Virology 2001, 290(1):143-152.
37. Wolffe E.J., Vijaya S., Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 1995, 211(1):53-63.
38. Xiang Y., Moss B. IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(20):11537-11542.